Clinical Trials on Urticaria in Hong Kong

Total 10 results

Prof. Lin Zhixiu

Recruiting

Modified Xiao-Feng Powder for Chronic Urticaria

Chronic Urticaria

Hong Kong
Hong Kong Sanatorium & Hospital

Terminated

Dietary Treatment for Chronic Urticaria (DTCU)

Diet Modification | Chronic Urticaria

China
Hong Kong Sanatorium & Hospital
Chinese University of Hong Kong; Stanford University

Completed

Mast Cell Activation Test in Allergic Disease

Asthma | Eczema | Food Allergy | Mastocytosis | Chronic Idiopathic Urticaria | Anaphylaxis | Mast Cell Activation Syndrome

Hong Kong
Novartis Pharmaceuticals

Recruiting

24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up

Chronic Spontaneous Urticaria

United States, Singapore, Spain, Germany, Turkey, Italy, Hong Kong, China, Malaysia, Argentina, Thailand, Poland, Japan, Netherlands, Chile, Canada
Novartis Pharmaceuticals

Recruiting

A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines

Chronic Inducible Urticaria

China, United States, Australia, Korea, Republic of, Israel, Turkey, Hong Kong, Malaysia, Singapore, Japan, Canada
Genentech, Inc.

Completed

A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria

Urticaria

United States
Genentech, Inc.

Completed

A Study of the Efficacy and Safety of Omalizumab (Xolair) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) Treatment

Chronic Idiopathic Urticaria

Germany, United States, Spain, Denmark, France, Poland, Turkey, Italy
Novartis Pharmaceuticals

Completed

A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines

Chronic Spontaneous Urticaria

United States, Croatia, Hungary, India, Malaysia, Spain, Germany, Austria, Czechia, Denmark, France, Korea, Republic of, Greece, Singapore, Thailand, Bulgaria, Argentina, Turkey, Guatemala, Brazil, Russian Federation, Peru, Canada, Sw... and more
CSL Behring

Active, not recruiting

Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks

Hereditary Angioedema

Australia, Canada, United States, New Zealand, Germany, Hong Kong, Netherlands, Taiwan, Czechia, Israel, Hungary, Japan, Russian Federation, Spain
BioCryst Pharmaceuticals

Completed

A Long Term Safety Study of BCX7353 in Hereditary Angioedema (APeX-S)

Hereditary Angioedema | Prophylaxis | HAE

Austria, Denmark, France, Germany, Hungary, Israel, Italy, North Macedonia, Poland, Switzerland, United Kingdom, United States, Australia, Hong Kong, Korea, Republic of, New Zealand, Serbia, Slovakia, South Africa, Spain

Clinical Trials on Urticaria in Hong Kong

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Morocco

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations